Olink announces that it has obtained CMA authorization for its project

UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK Competition and Markets Authority (the “CMA”) has unconditionally approved the previously announced public offer (the “Offer”) by Orion Acquisition AB (the “Purchaser”), a wholly-owned subsidiary of Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher” or the “Parent”), for all of the outstanding ordinary shares and American Depositary Shares (collectively, the “Shares”) of Olink for $26.00 per share.

The Offer is being made pursuant to the Purchase Agreement, dated October 17, 2023, between Thermo Fisher and Olink. Following approval by the CMA, Olink and Thermo Fisher expect to complete the Offer promptly following the expiration of the Offer at 5:00 p.m. Eastern Time on July 9, 2024 (“Expiration Time”).

The completion of the Offer remains subject to the conditions set forth in the Offer to Purchase, dated October 31, 2023 (together with any amendments or supplements thereto, the “Offer to Purchase”), including that the Purchaser holds Common Shares and American Depositary Shares that represent at least one Common Share of more than 90% of the Common Shares issued and outstanding immediately prior to the Expiration Time (excluding Common Shares held in treasury or by subsidiaries of Olink).

About Olink

Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics in collaboration with the scientific community, across multiple therapeutic areas to enable new discoveries and improve patients’ lives. Olink provides a platform of products and services that are deployed across leading pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of human biology in real time and advance 21st century healthcare through actionable and impactful science. The company was founded in 2016 and has a strong presence in Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

Investor Contact
David Deuchler
Managing Director of the Gilmartin Group
Phone: +1 917-209-5605
[email protected]

Media Contact
Michael B. Gonzales, Ph.D.
Vice President, Global Marketing
Mobile: +1 415 308 6467
[email protected]

Forward-Looking Statements

This press release contains forward-looking statements that involve a number of risks and uncertainties. Words such as “believe,” “anticipate,” “plan,” “expect,” “seek,” “estimate” and similar expressions are intended to identify forward-looking statements, but other statements that are not historical facts may also be deemed forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by the forward-looking statements include risks and uncertainties related to: the COVID-19 pandemic; the need to develop new products and adapt to significant technological changes; the implementation of strategies to enhance growth; general economic conditions and related uncertainties; dependence on customer capital expenditure policies and government financing policies; the effect of economic and political conditions and currency exchange rate fluctuations on international operations; the use and protection of intellectual property; the effect of changes in government regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that anticipated benefits related to recent or pending acquisitions, including the proposed acquisition, may not be realized as anticipated; the proposed acquisition not being completed in a timely manner, if at all; regulatory approvals required for the transaction not being obtained in a timely manner, if at all, or being obtained subject to conditions; prior to the completion of the transaction, Olink’s operations being disrupted due to uncertainty related to the transaction or other factors making it more difficult to maintain relationships with employees, customers, licensees, other business partners or governmental entities; difficulty in retaining key employees; the outcome of any legal proceedings related to the proposed acquisition; and the failure of the parties to successfully implement integration strategies or achieve expected synergies and operational efficiencies in the anticipated time frames or at all. Additional important factors that could cause actual results to differ materially from those indicated by these forward-looking statements are set forth in Thermo Fisher’s Annual Report on Form 10-K and subsequent Quarterly Report on Form 10-Q, which are filed with the U.S. Securities and Exchange Commission (“SEC”) and available in the “Investors” section of Thermo Fisher’s website, ir.thermofisher.com, under the heading “SEC Filings,” and in any subsequent documents that Thermo Fisher files or furnishes to the SEC, as well as in Olink’s Annual Report on Form 20-F and subsequent Interim Report on Form 6-K, which are filed with the SEC and available in the “Investor Relations” section of Olink’s website. https://investors.olink.com/investor-relationsunder the heading “SEC Filings,” and in all subsequent documents filed or furnished by Olink to the SEC. Although Thermo Fisher or Olink may elect to update forward-looking statements at some point in the future, Thermo Fisher and Olink expressly disclaim any obligation to do so, even if estimates change and, accordingly, you should not rely on these forward-looking statements as representing the views of Thermo Fisher or Olink as of any date subsequent to today.

Additional information and where to find it

This communication is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell shares of Olink common stock or American Depositary Shares or any other securities, nor is it a substitute for the tender offer documents that Thermo Fisher or the Purchaser have filed with the SEC. The terms and conditions of the tender offer are set forth in the Offer Statement and related offering materials prepared by Thermo Fisher and the Purchaser, and the offer to purchase shares of Olink common stock and American Depositary Shares is being made only pursuant thereto, and is being filed with the SEC in a Tender Offer Statement on Schedule TO. In addition, Olink has filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 regarding the Tender Offer.

THE TENDER OFFER DOCUMENTS (INCLUDING AN OFFER TO PURCHASE, A PUBLIC LETTER OF TRANSMITTAL TO PURCHASE, A FORM OF ACCEPTANCE OF SHARES AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF OLINK ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE TENDER OFFER FOR THEIR COMMON SHARES AND AMERICAN DEPOSITARY SHARES.

The tender offer materials, including the offer to purchase, the related ADS letter of transmittal and share acceptance form and certain other tender offer documents, as well as the solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or Olink, may be obtained free of charge at the SEC’s website at www.sec.govon the Olink website https://investors.olink.com/investor-relationson the Thermo Fisher website at www.thermofisher.com or by contacting Thermo Fisher Investor Relations at 781-622-1111. In addition, Thermo Fisher’s tender offer statement and other documents it files with the SEC will be available at https://ir.thermofisher.com/investors.